Quick Search:

uzh logo
Browse by:

Zurich Open Repository and Archive

Maintenance: Tuesday, July the 26th 2016, 07:00-10:00

ZORA's new graphical user interface will be relaunched (For further infos watch out slideshow ZORA: Neues Look & Feel). There will be short interrupts on ZORA Service between 07:00am and 10:00 am. Please be patient.

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-44391

Bordon, V; Gennery, A R; Slatter, M A; Vandecruys, E; Laureys, G; Veys, P; Friedrich, W; Qasim, W; Wulfraat, N M; Scherer, F; Cant, A J; Fischer, A; Cavazanna-Calvo, M; Bredius, R G M; Notarangelo, L D; Mazzolari, E; Neven, B; Güngör, T (2010). Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation. Blood, 116(1):27-35.

View at publisher


Cartilage-hair hypoplasia (CHH) is a rare autosomal recessive disease caused by mutations in the RMRP gene. Beside dwarfism, CHH has a wide spectrum of clinical manifestations including variable grades of combined immunodeficiency, autoimmune complications, and malignancies. Previous reports in single CHH patients with significant immunodeficiencies have demonstrated that allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for the severe immunodeficiency, while growth failure remains unaffected. Because long-term experience in larger cohorts of CHH patients after HSCT is currently unreported, we performed a European collaborative survey reporting on 16 patients with CHH and immunodeficiency who underwent HSCT. Immune dysregulation, lymphoid malignancy, and autoimmunity were important features in this cohort. Thirteen patients were transplanted in early childhood ( approximately 2.5 years). The other 3 patients were transplanted at adolescent age. Of 16 patients, 10 (62.5%) were long-term survivors, with a median follow-up of 7 years. T-lymphocyte numbers and function have normalized, and autoimmunity has resolved in all survivors. HSCT should be considered in CHH patients with severe immunodeficiency/autoimmunity, before the development of severe infections, major organ damage, or malignancy might jeopardize the outcome of HSCT and the quality of life in these patients.


16 citations in Web of Science®
18 citations in Scopus®
Google Scholar™



55 downloads since deposited on 02 Feb 2011
20 downloads since 12 months

Detailed statistics

Additional indexing

Contributors:Inborn Error Working Party of the European Bone Marrow Transplantation (EBMT) group
Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Children's Hospital Zurich > Medical Clinic
Dewey Decimal Classification:610 Medicine & health
Deposited On:02 Feb 2011 16:09
Last Modified:05 Apr 2016 14:42
Publisher:American Society of Hematology
Additional Information:This research was originally published in Blood. Copyright by the American Society of Hematology
Publisher DOI:10.1182/blood-2010-01-259168
PubMed ID:20375313

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page